Archive | February, 2014

Dr. Michael Har-Noy Describes The Potential Value Of AlloStimTM Infusion In HIV-Infected Patients

27 Feb

Dr. Michael Har-Noy, founder of the Israeli biotechnology company Immunovative Therapies, Ltd., indicates that HIV infection results in significant loss of the production of interferon.  Gamma interferon is a cytokine that is produced primarily from Th1 helper cells.  Gamma interferon is crucial for the suppression of viral replication.  Dr. Michael Har-Noy says that in cancer patients he has previously treated, intravenous infusion of AlloStimTM as produced a sustained state of inflammation – a “cytokine storm” – consisting of, in large part, secretion of copious amounts of serum gamma interferon.  Therefore, says Dr. Michael Har-Noy, AlloStimTM infusion in HIV-infected patients could potentially restore their ability to produce and sustain adequate plasma concentrations of gamma interferon, thereby enhancing their immunity to infection and augmenting their ability to suppress the HIV virus.

C-C chemokine receptor type 5 (CCR5) appears to function as the primary macrophage receptor for the HIV virus.  Dr. Michael Har-Noy says that interleukin-12 (IL-12) has been shown to significantly down-modulate the expression of CCR5 on the macrophage surface.  He adds that in the past, intravenous AlloStimTM infusion has resulted in a dramatic decrease in the expression of the CCR5 receptor.  Dr. Michael Har-Noy points out that in a previous patient (the “Berlin patient”), transplantation of donor immune cells that genetically lacked CCR5 receptors resulted in long-term HIV remission.  Dr. Michael Har-Noy hypothesizes that, since congenital lack of CCR5 receptors is rare, AlloStimTM infusion may be a viable alternative method of reducing CCR5 and therefore improving HIV resistance.

The allogeneic bone marrow transplant of CCR5 mutant immune cells into a HIV-infected patient resulted in long term remission from the HIV virus.  However, points out Dr. Michael Har-Noy, this treatment still required powerful pre-transplant chemotherapy and also carried a significant risk of deadly graft-versus-host disease (GVHD).  The immunologic phenomenon called “Mirror EffectTM” created by AlloStimTM infusion simulates the anti-tumor effects of al allogeneic bone marrow transplant without the potential for GVHD toxicity.  Dr. Michael Har-Noy thinks that this “Mirror EffectTM” may provide powerful anti-viral immunity in HIV patients without the risk of GVHD and without the need for a rare donor lacking the CCR5 receptor.

Dr. Michael Har-Noy is currently running a preliminary Phase I/II study of AlloStimTM in HIV-infected patients.  For more information, please visit www.immunocare.net

Advertisements

Dr. Michael Har-Noy Outlines A Few Potential Benefits Of AlloStimTM Administration In HIV Patients

21 Feb

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., an Israeli biotechnology company, says that in HIV infected people a switch in concentration of Th1 and Th2 helper cells occurs.  This causes suppression of a person’s natural cellular immunity.  Dr. Michael Har-Noy indicates that this helper cell switch is also correlated with the development of full-blown AIDS.  Correcting this Th1-Th2 imbalance in HIV infected patients might improve cellular immune function and prevent opportunistic infection.  Multiple intradermal AlloStimTM injections in cancer patients have induced a favorable Th2-Th1 reversal.  This phenomenon may be of great benefit to HIV infected patients.

In HIV infected patients, CD4+ cells are targeted by the HIV virus, causing low CD4+ counts and a lack of helper cell function.  Dr. Michael Har-Noy indicates that in HIV infected patients, remaining CD4+  helper cells are mostly of Th2 or Th0 variety, thereby resulting in poor cellular immunity.  Multiple intradermal AlloStimTM injections have been shown to increase circulating CD4+ Th1 memory cell titers.  Dr. Michael Har-Noy goes on to say that bolstering the CD4+ Th1 cell titer can restore helper function, as the HIV virus replicates primarily in Th2 cells.  Increasing the CD4+ Th1 memory cell count may be of great benefit, as these cells can resist HIV infection.

Dr. Michael Har-Noy says that interleukin 12 (IL-12) is significantly suppressed in patients with the HIV virus. IL-12, produced by mature dendritic cells and macrophages, is an important cytokine which promotes Th1 cellular immunity.  Intravenous infusion of AlloStimTM after intradermal priming raises serum IL-12 levels for months after administration.   Dendritic cells and macrophages that mature in the presence of IL-12 are resistant to infection by the HIV virus.  Therefore, says Dr. Michael Har-Noy, restoration of IL-12 production by these mature dendritic cells should strengthen Th1 cellular immunity in HIV-infected patients.

Dr. Michael Har-Noy is currently conducting a Phase I/II pilot study of AlloStimTM administration in HIV-infected patients.  For more information, visit www.immunocare.net